Source:http://linkedlifedata.com/resource/pubmed/id/16626762
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2006-7-17
|
| pubmed:abstractText |
Acute and fulminant liver failure induced by viral hepatitis, alcohol or other hepatotoxic drugs are associated with tumor necrosis factor (TNF) production. D-Galactosamine (D-GalN) and lipopolysaccharide (LPS)-induced liver injury is an experimental model of fulminant hepatic failure. In this model, TNF-alpha plays a central role in the pathogenesis of D-GalN/LPS-induced liver injury in mice. Y-40138, N-[1-(4-[4-(pyrimidin-2-yl)piperazin-1-yl]methyl phenyl)cyclopropyl] acetamide.HCl inhibits TNF-alpha and augments interleukin (IL)-10 production in LPS-injected mice in plasma. In the present study, we examined the effect of Y-40138 on D-GalN/LPS-induced hepatitis. Y-40138 (10mg/kg, i.v.) significantly suppressed TNF-alpha and monocyte chemoattractant protein-1 (MCP-1) production and augmented IL-10 production in plasma. In addition, Y-40138 significantly inhibited TNF-alpha production induced by direct interaction between human T lymphocytes and macrophages. Y-40138 suppressed plasma alanine transaminase (ALT) elevation and improved survival rate in D-GalN/LPS-injected mice, and it is suggested that the protective effect of Y-40138 on hepatitis may be mediated by inhibition of TNF-alpha and MCP-1, and/or augmentation of IL-10. This compound is expected to be a new candidate for treatment of cytokine and/or chemokine-related liver diseases such as alcoholic hepatitis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Acetamides,
http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase,
http://linkedlifedata.com/resource/pubmed/chemical/Ccl2 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CCL2,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokines,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Galactosamine,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Y 39041
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0024-3205
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
24
|
| pubmed:volume |
79
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
822-7
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:16626762-Acetamides,
pubmed-meshheading:16626762-Alanine Transaminase,
pubmed-meshheading:16626762-Animals,
pubmed-meshheading:16626762-Cell Death,
pubmed-meshheading:16626762-Chemokine CCL2,
pubmed-meshheading:16626762-Chemokines,
pubmed-meshheading:16626762-Coculture Techniques,
pubmed-meshheading:16626762-Cytokines,
pubmed-meshheading:16626762-Drug-Induced Liver Injury,
pubmed-meshheading:16626762-Female,
pubmed-meshheading:16626762-Galactosamine,
pubmed-meshheading:16626762-Hepatocytes,
pubmed-meshheading:16626762-Lipopolysaccharides,
pubmed-meshheading:16626762-Liver,
pubmed-meshheading:16626762-Macrophages,
pubmed-meshheading:16626762-Mice,
pubmed-meshheading:16626762-Mice, Inbred BALB C,
pubmed-meshheading:16626762-Piperazines,
pubmed-meshheading:16626762-T-Lymphocytes,
pubmed-meshheading:16626762-Tumor Necrosis Factor-alpha
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Y-40138, a multiple cytokine production modulator, protects against D-galactosamine and lipopolysaccharide-induced hepatitis.
|
| pubmed:affiliation |
Marketing and Planning Department, Sales and Marketing Division, Mitsubishi Pharma Corporation, 2-5-6 Awaji-machi, Chuo-ku, Osaka 541-0047, Japan. Fukada.Tetsuko@mf.m-pharma.co.jp
|
| pubmed:publicationType |
Journal Article
|